Skip to content Skip to sidebar Skip to footer

Newsletter

Life Sciences

Proteomics has launched 2 Promarker tests in a matter on months and is about to launch a 3rd

Proteomics' suite of Promarker tests are all being launched in 2025.The range includes:PromarkerD for DKD which has been launched in Australia and the USA; PromarkerEso for Esophageal cancer which is now commercially available in Australia, and PromarkerEndo for Endometriosis which will be commercialised shortly.Launching 3 tests in a a year is…

ByNick SundichSeptember 26, 2025

Amplia Therapeutics (ASX:ATX): Battling pancreatic cancer with an FAK inhibitor

Amplia Therapeutics (ASX:ATX) is another ASX oncology biotech company, attempting to battle cancer. At first glance, it may not a unique company but when you dig deeper...it is. It is using an 'FAK inhibitor' to fight pancreatic cancer (and potentially other indications down the track). What are the Best ASX Stocks to invest in right now?…

ByNick SundichSeptember 23, 2025

Nexsen: Another ‘point of care diagnostics’ company is about to hit the ASX

There's another company about to join the cohort of ASX biotech stocks and its name is Nexsen. Nexsen is proposed to list on Tuesday October 7, raising $6m at 20c per share, and to have the code NXN. This company has a rapid sensing technology that it will first commercialise to detect Group B Streptococcus…

ByNick SundichSeptember 19, 2025

Emyria’s (ASX:EMD) commercial breakthrough in psychedelic medicine

When Perth-based Emyria (ASX:EMD) announced on 18 June that Medibank would be funding eligible customer participation in Emyria's Post-Traumatic Stress Disorder care programme, with no out-of-pocket costs, investors who know the Life Sciences sector needed to sit up and take notice. Here was Australia's largest health insurer, with over 4.2 million customers, saying that it…

ByStuart RobertsSeptember 10, 2025

Actinogen Medical (ASX:ACW): Will history repeat itself? Can it bounce back from a troublesome Phase 2 trial?

Actinogen Medical (ASX:ACW) is the poster child for how volatile biotech stocks can be. the last time we wrote about this company was in August last year when shares more than halved after results of a Phase II trial that investors perceived to be a flop. But the company has soldiered on and has a…

ByNick SundichSeptember 9, 2025

4D Medical (ASX:4DX) could become the next Pro Medicus, and its taken some important strides in 2025!

There's not many Australian radiology companies that seek to conquer the USA, but 4D Medical (ASX:4DX) is one of them. Another one was Pro Medicus (ASX:PME), and everyone knows how that story turned out - that stock is now worth over $11bn, all because of runaway success in the US market. 4D Medical shareholders inevitably…

ByNick SundichSeptember 2, 2025

ASX stocks in America: Here are 4 performing well and 4 performing poorly

You might think ASX stocks in America are doing better than peers which are not there because the USA is a much bigger market. In reality, this is not always the case. What are the Best ASX Stocks to invest in right now? Check our buy/sell tips[sg_popup id="23914" event="click"][/sg_popup] ASX stocks in America: Here are 4 performing…

ByNick SundichSeptember 2, 2025

Blinklab (ASX:BB1): Is this exciting company the next ResApp?

Blinklab (ASX:BB1) is the answer to the question of how you could help children with autism - a response that begins with 'there's an app for that'.There is precedent for app-based health companies to succeed, just look at ResApp (ASX:RAP), which was bought by Pfizer for $179m back in 2022. The former chairman of that…

ByNick SundichAugust 29, 2025

Nova Eye Medical (ASX:EYE) has been on a strong run, up 50% in one month. Is there more upside?

Nova Eye Medical (ASX:EYE) is no clinical stage medtech company, but has just an exciting 12 months ahead as if it was a clinical stage company with company-making catalysts ahead.Because even though it has commercialised its devices, a major 12 months are ahead during which it is expected to make major inroads in the US…

ByNick SundichAugust 27, 2025

Here are 5 ASX biotechs expecting clinical trial results in the next few months!

Here are 5 ASX biotechs expecting clinical trial results in the next few months! Dimerix (ASX:DXB) Dimerix is in the middle of a Phase III trial or its DMX-200 drug for a condition known as Focal Segmental Glomerulosclerosis (FSGS). For patients with FSGS, the kidneys’ ability to purify (clean) the blood is impaired. This can…

ByNick SundichAugust 27, 2025

the Kick-ass Multipurpose WordPress Theme

Life Sciences

Proteomics has launched 2 Promarker tests in a matter on months and is about to launch a 3rd

Amplia Therapeutics (ASX:ATX): Battling pancreatic cancer with an FAK inhibitor

Nexsen: Another ‘point of care diagnostics’ company is about to hit the ASX

Emyria’s (ASX:EMD) commercial breakthrough in psychedelic medicine

Actinogen Medical (ASX:ACW): Will history repeat itself? Can it bounce back from a troublesome Phase 2 trial?

4D Medical (ASX:4DX) could become the next Pro Medicus, and its taken some important strides in 2025!

ASX stocks in America: Here are 4 performing well and 4 performing poorly

Blinklab (ASX:BB1): Is this exciting company the next ResApp?

Nova Eye Medical (ASX:EYE) has been on a strong run, up 50% in one month. Is there more upside?

Here are 5 ASX biotechs expecting clinical trial results in the next few months!

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Life Sciences

Stocks in Spotlight

Add Your Heading Text Here